UNLIMITED TURBO BULL - PHARMING GROUP Stock

UNLIMITED TURBO BULL - PHARMING GROUP Share Price

CF17Z

DE000CJ3QAZ3

Market Closed - Euronext Paris 17:30:00 26/04/2024 BST
0.229 ^EUR	+8.02%

Current month	-35.85%
1 month	-34.57%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart PHARMING GROUP N.V.

Chart UNLIMITED TURBO BULL - PHARMING GROUP

Latest news about PHARMING GROUP N.V.

Pharming N : Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 - Form 6-K	04-25	PU
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders 2024 Rare Impact Awards	04-25	AQ
Pharming N : to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards - Form 6-K	04-24	PU
Pharming N : Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards	04-24	PU

More news

Quotes 5-day view

Date	Price	Change	Volume
26/04/24	0.229	+8.02%	22,750
25/04/24	0.212	-8.23%	117,300
24/04/24	0.231	-4.15%	61
23/04/24	0.241	+5.24%	41,000
22/04/24	0.229	+8.53%	23,764

Real-time Euronext Paris

Last update April 26, 2024 at 05:30 pm

More quotes

Static data

Product type	Certificat Turbo Stop Loss
Buy / Sell	CALL
Underlying	PHARMING GROUP N.V.
Issuer	Société Générale
	CF17Z
ISIN	DE000CJ3QAZ3
Date issued	14/11/2018
Strike	0.6705 €
Maturity	Unlimited
Parity	1 : 1
Emission price	0.38 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.075 €
Lowest since issue	0.09 €

Company Profile

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.

Sector

More about the company

Ratings for Pharming Group N.V.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Pharming Group N.V.

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9 EUR

Average target price

2 EUR

Spread / Average Target

+122.22%

Consensus